| Literature DB >> 29579302 |
Malin Inghammar1,2, Laurence Borand1, Sophie Goyet1, Blandine Rammaert3,4, Vantha Te5, Patrich Lorn Try6, Bertrand Guillard1, Philippe Buchy1,7, Sirenda Vong1, Eap Tek Chheng1, Philippe Cavailler1, Charles Mayaud8, Arnaud Tarantola1.
Abstract
Background: In Western settings, community-acquired pneumonia (CAP) due to Gram-negative bacilli (GNB) is relatively rare. Previous studies from Asia, however, indicate a higher prevalence of GNB in CAP, but data, particularly from Southeast Asia, are limited.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29579302 PMCID: PMC6018679 DOI: 10.1093/trstmh/try022
Source DB: PubMed Journal: Trans R Soc Trop Med Hyg ISSN: 0035-9203 Impact factor: 2.184
Figure 1.Flowchart of cohort selection, SISEA study, 2007–2010, Cambodia.
Demographic and clinical characteristics in CAP patients with and without GNB, SISEA study, 2007–2010, Cambodia
| GNBa | Non-GNBb | p-Value | ORc | 95% CI | Missing information, n | |
|---|---|---|---|---|---|---|
| Participants | 97 | 1326 | ||||
| Age (y), median (IQR) | 50 (42–61) | 55 (42–66) | 0.15 | 1.0 | 1.0 to 1.0 | |
| Male, n (%) | 45 (46.4) | 689 (52.0) | 0.29 | 1.2 | 0.8 to 1.9 | |
| Smoker, n (%) | 17 (17.5) | 302 (22.8) | 0.23 | 0.7 | 0.4 to 1.2 | |
| Alcohol, n (%) | 13 (13.4) | 237 (17.9) | 0.26 | 0.7 | 0.4 to 1.3 | |
| Previous antibiotics, n (%) | 14 (14.4) | 118 (8.9) | 0.07 | 1.7 | 0.9 to 3.1 | |
| Previous treatment, n (%) | 54 (55.7) | 681 (51.4) | 0.41 | 1.2 | 0.8 to 1.8 | |
| Comorbidities | ||||||
| At least 1 comorbidity, n (%) | 17 (17.5) | 226 (17.0) | 0.90 | 1.0 | 0.6 to 1.8 | |
| Diabetes, n (%) | 8 (8.3) | 43 (3.2) | 0.01 | 2.7 | 1.2 to 5.9 | |
| Renal disease, n (%) | 1 (1.0) | 10 (0.75) | 0.76 | 1.4 | 0.2 to 10.8 | |
| Cardiac disease, n (%) | 6 (6.2) | 138 (10.4) | 0.18 | 0.6 | 0.2 to 1.3 | |
| Liver disease, n (%) | 0 | 15 (1.1) | 0.62 | n.a. | n.a. | |
| Malignancy, n (%) | 1 (1.0) | 1 (0.08) | 0.13 | 13.8 | 0.9 to 222.3 | |
| Pulmonary disease, n (%)d | 11 (11.3) | 192 (14.5) | 0.39 | 0.8 | 0.4 to 1.4 | |
| HIV, n (%) | 1 (1.0) | 20 (1.5) | 0.71 | 0.7 | 0.1 to 5.1 | —e |
| Clinical characteristics | ||||||
| CRB-65 score, n (%) | 0.93 | |||||
| 0 | 42 (43.3) | 592 (44.7) | 1 | Ref. | ||
| 1–2 | 54 (55.7) | 716 (54.0) | 1.0 | 0.7 to 1.6 | ||
| 3–4 | 1 (1.0) | 18 (1.4) | 0.8 | 0.1 to 6.0 | ||
| Severe CAP, n (%) | 14 (14.4) | 101 (7.6) | 0.02 | 2.0 | 1.1 to 3.7 | |
| Dyspnea, n (%) | 75 (77.3) | 900 (67.9) | 0.05 | 1.6 | 1.0 to 2.6 | |
| Hypoxemia, n (%) | 11 (11.3) | 83 (6.3) | 0.05 | 1.9 | 1.0 to 3.7 | |
| Productive cough, n (%) | 77 (79.4) | 948 (71.5) | 0.10 | 1.5 | 0.9 to 2.5 | |
| Haemoptysis, n (%) | 12 (13.5) | 104 (8.2) | 0.09 | 1.7 | 0.9 to 3.3 | |
| Headache, n (%) | 21 (21.7) | 169 (12.9) | 0.01 | 1.9 | 1.2 to 3.2 | |
| Fever on admission, n (%) | 42 (43.3) | 459 (34.6) | 0.08 | 1.4 | 0.9 to 2.2 | |
| Lab results | ||||||
| Leucocyte count, ×109/l, median (IQR) | 10.2 (6.4–13.8) | 8.4 (6.2–11.2) | <0.01 | 1.1 | 1.0 to 1.1 | 4 |
| Leucocyte count >15×109/l, n (%) | 21 (21.7) | 141 (10.7) | <0.01 | 2.3 | 1.4 to 3.9 | 4 |
| AST, median U/l (IQR) | 26 (23–41) | 31 (24–42) | 0.15 | 1.0 | 1.0 to 1.0 | 81 |
| ALT, median U/l (IQR) | 28 (21–41) | 28 (21–36) | 0.48 | 1.0 | 1.0 to 1.0 | 85 |
| Creatinine μmol/l (IQR) | 89 (73–112) | 89 (77–110) | 0.39 | 1.0 | 1.0 to 1.0 | 95 |
| Radiology | ||||||
| Consolidation, n (%) | 20 (20.6) | 200 (15.1) | 0.15 | 1.5 | 0.9 to 2.4 | |
| Interstitial infiltrates, n (%) | 8 (8.3) | 203 (15.3) | 0.06 | 1.4 | 0.9 to 2.1 | |
| Alveolar infiltrates, n (%) | 65 (67.0) | 792 (59.7) | 0.16 | 0.5 | 0.2 to 1.0 | |
| Cavitation, n (%) | 30 (31.3) | 402 (30.4) | 0.87 | 1.0 | 0.7 to 1.6 | |
| Pleural effusion, n (%) | 23 (23.7) | 389 (29.3) | 0.24 | 0.7 | 0.5 to 1.2 | |
| Outcome | ||||||
| Death, n (%) | 10 (10.3) | 45 (3.4) | <0.01 | 3.2 | 1.6 to 6.7 | |
| Time to death (y), median (IQR) | 2 (0–2) | 3 (1–5) | 0.01 | |||
| Correct antibiotic, n (%)f | 12 (19.1) | 70 (81.4) | <0.01 | —f | ||
CRB-65: confusion, respiratory rate, blood pressure, 65 years of age and older; n.a.: not available; Ref.: reference.
aNon-haemophilus Gram-negative bacilli (Enterobactreiaceae, non-fermenters, Acinetobacter spp., B. pseudomallei).
bCAP from all other causes, including CAP of unknown aetiology.
cEstimated by logistic regression.
dDefined as chronic bronchitis or asthma, emphysema, bronchiectasis or other infectious sequelae on chest X-ray.
eHIV testing followed provider-initiated testing according to national Cambodian guidelines. In this cohort, 60% of the participants were tested for HIV on admission.
fCalculated in those whose bacteriology could be assigned with available data on antibiotic treatment and antibiotic susceptibility testing (n=149).
Predictors of CAP due to GNB, SISEA study, 2007–2010, Cambodia
| Adjusted OR | 95% CI | p-Value | |
|---|---|---|---|
| Diabetes | 2.6 | 1.2 to 5.8 | 0.02 |
| Headache | 1.8 | 1.1 to 3.0 | 0.03 |
| Leucocyte count >15×109/l | 1.9 | 1.1 to 3.3 | 0.02 |
| Severe CAP | 1.9 | 1.0 to 3.4 | 0.05 |
Estimated by logistic regression in 1406 individuals, adjusted for all other variables in the table. The area under the receiver operating characteristics curve was 0.71.
Predictors of mortality, SISEA study, 2007–2010, Cambodia
| Adjusted OR | 95% CI | p-Value | |
|---|---|---|---|
| GNB | 3.0 | 1.4 to 6.4 | <0.01 |
| Severe CAP | 4.5 | 2.4 to 8.4 | <0.01 |
| Comorbiditya | 2.9 | 1.6 to 5.2 | <0.01 |
Estimated by logistic regression in 1423 patients, adjusted for all other variables in the table.
aAt least one of either: diabetes, renal disease, pulmonary disease, liver disease or cardiac disease.